Investor Presentation Q1 2023

89 Investor presentation First three months of 2023 Ziltivekimab aspires to address an unmet need in more than 5 million people in patients with ASCVD, CKD and inflammation Ziltivekimab aspires to reduce MACE in people with ASCVD and CKD Critical success factors to commercialise ziltivekimab Global patients (in millions) 16 12 Approximately 5-8m patients 8 4 0 ASCVD with CKD hsCRP>2 Market building Focus areas Targeted HCP outreach and relationship building Successful payer engagement • • Increase presence with key prescriber base being cardiologists and PCPS Enhance awareness of inflammatory burden in CVD with KOLs and HCP associations Utilise ZEUS read-out to quantify anti- inflammatory clinical benefit in ASCVD patients with CKD vs Standard of Care Integrated evidence generation • Understand hsCRP and inflammation, epidemiology of disease and socio-economic burden of disease ○ Low High 1 Includes US, EU5 (Germany, France, Spain, Italy, United Kingdom) and Japan MACE or major adverse cardiovascular events includes CV death, non-fatal MI or non-fatal stroke; ASCVD: Atherosclerotic cardiovascular disease; CKD: Chronic kidney disease; HCP: Healthcare professional; PCP: Primary care physician KOL: Key opinion leader; hsCRP: High-sensitivity C-reactive protein Novo NordiskⓇ Investment levels

View entire presentation